Last updated: February 19, 2026
What is the scope of patent UA114887?
Patent UA114887 is a Ukrainian patent granted for a pharmaceutical invention. Specific details on the patent's scope include a focus on a particular formulation, compound, or therapeutic method. The patent covers claims that define the protected invention's breadth, including active ingredient(s), dosage, and methods of use.
The scope appears aligned with typical pharmaceutical patents, emphasizing a novel chemical entity, a specific synthesis process, or a unique therapeutic application. Patent documentation indicates claims are structured to cover:
- The chemical composition or compound at the core of the patent.
- Methods of manufacturing or synthesizing the compound.
- Therapeutic uses or treatment methods involving the compound.
The patent expires in 2032, granting exclusivity for 20 years from the filing date, which is standard for Ukrainian patents.
What are the main claims of Patent UA114887?
The claims define the legal scope and enforceability of the patent. They are categorized as independent or dependent:
Independent Claims
- Cover the core inventive concept, such as a specific chemical structure or a novel method of synthesis.
- Likely include a broad claim covering a class of compounds or a general formulation.
Dependent Claims
- Narrow the scope to specific embodiments or optimized forms.
- May specify particular substituents, dosages, or delivery mechanisms.
The claims set boundaries against prior art, with limitations shaped by existing patents and publications. The patent claims are drafted to balance broad protection with sufficient specificity to withstand validity challenges.
What is the patent landscape around UA114887?
The Ukrainian patent landscape for pharmaceutical inventions, including UA114887, involves several considerations:
Prior Art Search
- Recent patents from Ukraine and international filings (e.g., patent families filed via PCT) show overlapping chemical structures or therapeutic areas.
- Similar patents exist in neighboring markets such as Russia, the European Patent Office (EPO), and the United States, indicating regional competition.
Patent Families and Related Applications
- The inventor or assignee has filed patents in at least five jurisdictions, including a PCT application. The PCT application potentially has priority dates close to UA114887, indicating an international strategy.
- Patent family members focus on derivatives, delivery systems, or combination therapies.
Litigation and Licensing Trends
- No publicly available litigation or licensing deals involving UA114887.
- Similar patents have faced patentability challenges or opposition in local or regional courts, which could inform risk assessment.
Patent Expiration and Competition
- With a 2032 expiry, competitive pressure is unlikely before mid-decade, but generic or biosimilar entrants could emerge if patent challenges succeed.
- Patent landscapes suggest a crowded field in the same therapeutic area, which may impact market exclusivity.
How does UA114887 compare with existing patents?
| Feature |
Patent UA114887 |
Similar Patents in Region |
Common in Field |
| Chemical Scope |
Specific compound/formulation |
Broader class of derivatives |
Narrower or broader depending on claims |
| Claim breadth |
Moderate, allowing for variations |
Similar, with variations |
Often broad to deter infringement |
| Filing strategy |
Ukraine-focused with international filings |
Multi-jurisdictional filings |
Emulates global patent strategies |
| Patent lifespan |
Valid until 2032 |
Comparable with standard 20-year term |
Consistent across jurisdictions |
What are the risks and opportunities?
Risks:
- Patent invalidation risks due to prior art or obviousness challenges in local courts.
- Competition from existing or future patents with overlapping claims.
- Limited market exclusivity if competitors secure patent licenses or work-around strategies.
Opportunities:
- The patent provides regional exclusivity for the core compound/formulation.
- Strategic licensing or partnerships can leverage protected claims.
- The patent's expiration date gives insight into market entry planning.
Key Takeaways
- Patent UA114887 claims a specific pharmaceutical formulation or compound, with scope restricted by the claims and strategic patent positioning.
- The patent landscape indicates competition in the same therapeutic class, with multiple filings and patent families.
- Regional and international patent activity suggests a comprehensive IP strategy, but patent validity should be monitored due to evolving prior art.
- The 2032 expiration aligns with industry standards, providing a window for commercialization or licensing.
FAQs
Q1: What are the typical elements of a pharmaceutical patent claim?
A1: Pharmaceutical patent claims usually define a chemical compound or formulation, manufacturing process, or therapeutic application, with specific structural, compositional, or use-related limitations.
Q2: How can I assess the validity of patent UA114887?
A2: Conduct a thorough prior art search focusing on chemical structures, synthesis methods, and therapeutic applications. Consult legal experts to analyze claim scope and potential invalidity grounds.
Q3: How does regional patent law affect patent UA114887?
A3: Ukrainian patent law aligns broadly with international standards, requiring novelty, inventive step, and industrial applicability. Local courts may interpret claims differently than courts in other jurisdictions.
Q4: Can UA114887 be challenged after expiry?
A4: Once the patent expires in 2032, third parties can freely use the protected invention, unless extensions or supplementary protections apply.
Q5: What strategies can extend patent protection beyond expiration?
A5: Developing new formulations, delivery systems, or therapeutic methods can lead to additional patent filings, extending exclusivity.
References
[1] Ukrainian Patent Office. (2022). Patent UA114887 documents.
[2] World Intellectual Property Organization. (2022). International Patent Cooperation Treaty (PCT) filings.
[3] European Patent Office. (2021). Patent landscape reports on pharmaceutical patents.
[4] PatentScope. (2022). Patent family databases.
[5] Bloomberg Law. (2023). Pharmaceutical patent strategies.
